Ribogenics is a developer of small molecule RNA-medicines to treat cancer, neurological disorders, and rare diseases. The company's platform Ribogenics Platform generates small molecule drug candidates that can correct the function, presence or absence of proteins enabling cells to operate normally with a validated high-throughput phenotypic